Business Fortune
In the world of biopharmaceuticals, the need for innovative, reliable, and efficient solutions has never been more critical. Bionova Scientific® stands at the forefront of this industry, blending cutting-edge technology with scientific excellence to accelerate the development of biotherapeutics. Founded with the vision to address the toughest challenges in biologics manufacturing, Bionova is revolutionizing the way protein therapeutics are brought to market. Their commitment to advancing healthcare, improving patient outcomes, and streamlining biomanufacturing is paving the way for a healthier future.
A World-Class Facility Backed by Global Expertise
At the core of Bionova's operations is a state-of-the-art facility that rivals companies many times its size. With the backing of Asahi Kasei, a global powerhouse, Bionova continues to set new standards in bio-productivity. From early-stage cell line development to large-scale commercial biomanufacturing, the company employs robust, scalable processes that help biopharma companies develop effective, high-quality molecules more efficiently and faster.
The company's philosophy is clear: reducing the wait time between innovation and patient care. Their work is driven by the knowledge that every step they take brings a cure closer to those who need it. Bionova’s commitment to shaving off crucial time and ensuring quality is central to their service offerings.
The Power of Expertise, Equipment, and Client-Centric Care
Three key attributes define Bionova’s success: capability, equipment, and a client-centered approach. The company’s founders were experts in cell line development and GMP manufacturing, and they’ve carried that scientific expertise into the heart of Bionova. Today, the company boasts a team of leading scientists and engineers, ensuring that clients receive the most effective solutions, whether they’re tackling complex technical challenges or seeking to improve product quality.
What truly sets Bionova apart, however, is their unwavering commitment to client success. The team is passionate about not only delivering high-quality scientific outcomes but also going above and beyond to ensure that every client feels valued. This dedication to service has earned Bionova a reputation for excellence and made them a trusted partner for companies looking to accelerate their product development.
Advanced Protein Production Services for Accelerated R&D
Bionova Scientific provides rapid protein production services designed to meet the evolving needs of biopharmaceutical research. Utilizing both transient and stable transfection techniques, the company accelerates proof-of-concept activities, delivering research material in gram quantities for studies and other applications. Their flexible production capabilities range from small-scale shake flasks to larger 50L cell culture batches, ensuring that clients have the exact amount of material they need, on time and to specification.
The company’s protein purification process includes standard column chromatography steps, with additional services such as protein concentration, endotoxin testing, and protein aggregation analysis. Custom formulations are also available to ensure stability, and Bionova’s team offers a range of analytical services to meet the unique needs of each client.
Innovative Research Material Generation and High-Throughput Protein Production
Bionova’s deep expertise spans a wide array of protein types, including monoclonal antibodies, polyclonal antibodies, glycoproteins, enzymes, Fc-fusion enzymes, and bi-specific antibodies. Their high-throughput protein production platform, which supports both transient production in CHO and HEK 293 cells and stable pool production at scale, enables clients to rapidly generate the research material needed to advance their projects.
Whether clients need research material for discovery work or for refining upstream, downstream, and analytical development, Bionova has the capability to support every stage of the process. Their versatile production methods include incubator shakers, WAVE bioreactors, and stirred tank bioreactors, ensuring that clients’ unique needs are met with flexibility and precision.
Cell Line Development: Building Robust Foundations for Biopharma Success
At the heart of Bionova’s services is their expertise in mammalian cell line development. Bionova’s cell line development team focuses on optimizing DNA sequences and ensuring the creation of robust, high-productivity cell lines. The company understands that the success of a biopharma product depends heavily on the strength of the cell line, and they dedicate themselves to rapidly developing high-yield, high-quality cell lines that meet the specific needs of their clients.
Bionova excels in solving challenges related to expression, productivity, and product quality, and they take a proactive approach to identify and address potential issues early on. Their commitment to producing cell lines that meet or exceed client expectations is a key factor in their success. The company’s cell line development team has been involved in numerous IND and BLA filings, cementing Bionova’s position as a go-to partner for critical cell line development programs.
The Road Ahead
Looking forward, Bionova remains committed to advancing the field of biopharmaceutical manufacturing. Their focus on innovation, collaboration, and continuous improvement ensures that they will remain a leading player in the biotech sector. The company continues to invest in new technologies, refine their processes, and expand their capabilities to meet the ever-changing demands of the biopharma industry.
As they continue to push the boundaries of what’s possible in protein production and cell line development, Bionova’s dedication to their clients’ success remains unwavering. For Bionova, the work isn’t just about building better biologics—it’s about building better futures for patients around the world.
About | Darren Head
Darren Head is the Chairman and President of Bionova Scientific®. He also served as Chairman of Bionova’s Board of Directors from 2019 until the company was acquired by Asahi Kasei in 2022. Darren also serves as CEO of Cellipont Bioservices, a cell therapy CDMO based in the San Diego area.
Mr. Head holds a B.S. in biology and attended the executive M.B.A. program at Texas A&M. Additionally, he served in the United States Air Force during Operation Desert Storm.
